SmallCapReview.com has been a leading site for information on small cap stocks, penny stocks and microcaps since 1999.
Compugen (Nasdaq: CGEN) $3.89. Today announced that administration of CGEN-15001 in an animal model of rheumatoid arthritis (RA) dramatically ameliorates the clinical symptoms of the disease. These results, combined with earlier results in an animal model of multiple sclerosis (MS), strongly support the therapeutic potential of CGEN-15001 for multiple autoimmune diseases and inflammatory conditions.
The recently completed study of CGEN-15001 utilized the collagen-induced arthritis (CIA) animal model. This well accepted animal model of RA manifests an autoimmune disease with clinical and pathological similarity to human rheumatoid arthritis. Upon treatment of mice with established RA disease, impressive therapeutic effects of CGEN-15001 were observed. Furthermore, CGEN-15001 showed efficacy similar to that observed through TNF-alpha blockade with TNFR-Fc, ENBREL, a widely used biologic disease modifying anti-rheumatic drug (DMARD). In the study, both ENBREL and CGEN-15001 were administered at the same dose and frequency.
What They Do: Compugen is a leading drug and diagnostic product candidate discovery company.
ISTA Pharmaceuticals (Nasdaq: ISTA) $4.56. Today announced it has initiated a Phase 2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies. The randomized, placebo-controlled, parallel-group environmental study will evaluate the safety and efficacy of bepotastine besilate, dosed twice daily, in patients presenting with allergic rhinitis caused by one of the most potent seasonal allergy triggers, Mountain Cedar pollen.
ISTA expects to enroll approximately 600 patients in Texas who will be treated with either bepotastine besilate nasal spray or placebo for two weeks. Patients will grade both individual nasal and ocular symptoms on a daily basis.
What They Do: ISTA Pharmaceuticals, Inc., is the fourth largest and fastest growing branded prescription eye care business in the United States, with an expanding focus on allergy therapeutics.
CECO Environmental (Nasdaq: CECE) $5.53. Today announced that it has received a new order for $1.5 million from a Canadian refinery. Jeff Lang, CECO's Chief Executive Officer, commented, "I am very pleased that CECO continues to grow our global order backlog. This new order is from our aftermarket business which continues to generate increasing momentum and sales. We look forward to ending the year and beginning 2011 with a strong backlog and an industry poised for further growth."
What They Do: CECO Environmental Corp. is North America's largest independent air pollution control company.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play, to register visit www.SmallCapReview.com.
